ETF Managers Group’s Sarepta Therapeutics SRPT Stock Holding History

ETF Managers Group’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4,569	Closed	-$592K	–	738
2022 Q4	$592K	Buy	+4,569	New	+$529K	0.03%	312

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ETF Managers Group's SRPT Position: Q1 2023 in Review

ETF Managers Group sold out of Sarepta Therapeutics (SRPT) in Q1 2023, closing a stake of 4,569 shares — an estimated $592K sold.

ETF Managers Group first reported a position in SRPT in Q4 2022 and held it in 1 quarter. The position peaked at $592K in Q4 2022. 426 funds tracked by Wall St. Rank hold SRPT as of Q1 2023.

ETF Managers Group reported no remaining Sarepta Therapeutics position as of Q1 2023 after selling out during the quarter.
ETF Managers Group sold 4,569 Sarepta Therapeutics shares in Q1 2023, an estimated $592K.
ETF Managers Group first reported a position in Sarepta Therapeutics in Q4 2022 and held it in 1 quarter.
ETF Managers Group's Sarepta Therapeutics position peaked at $592K in Q4 2022.
426 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2023.

Based on ETF Managers Group's 13F filing for Q1 2023, filed 18 Apr 2023.